NCLH vs RNAZ · P/E 16, rev $4.97B vs $5.1M cap
Norwegian Cruise Line Holdings Ltd (NCLH) versus Transcode Therapeutics Inc (RNAZ) — a side-by-side from cached financials, not a winner call.
Norwegian Cruise Line Holdings Ltd (NCLH) is a travel services company listed on NYSE.
Transcode Therapeutics Inc (RNAZ) is a biotechnology company listed on NASDAQ.
Latest reported NCLH revenue for 2026-06-30 was $4.97B. Net income was $327.2M. NCLH currently screens at market cap $9.10B and trailing P/E 16.0.
RNAZ does not have a complete income-statement cache yet.
NCLH currently screens at market cap $9.10B and trailing P/E 16.0. RNAZ currently screens at market cap $5.1M.
Not investment advice. Open the NCLH and RNAZ stock pages for the full models.
Not investment advice.